BLEPH-10 Drug Patent Profile
When do Bleph-10 patents expire, and when can generic versions of Bleph-10 launch?
Bleph-10 is a drug marketed by Allergan and is included in two NDAs.
The generic ingredient in BLEPH-10 is sulfacetamide sodium. There is one drug master file entry for this compound. Nine suppliers are listed for this compound. Additional details are available on the sulfacetamide sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Bleph-10
A generic version of BLEPH-10 was approved as sulfacetamide sodium by CHARTWELL RX on October 18th, 1988.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for BLEPH-10?
- What are the global sales for BLEPH-10?
- What is Average Wholesale Price for BLEPH-10?
Summary for BLEPH-10
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Patent Applications: | 4,733 |
| DailyMed Link: | BLEPH-10 at DailyMed |
US Patents and Regulatory Information for BLEPH-10
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergan | BLEPH-10 | sulfacetamide sodium | OINTMENT;OPHTHALMIC | 084015-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Allergan | BLEPH-10 | sulfacetamide sodium | SOLUTION/DROPS;OPHTHALMIC | 080028-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
